---
layout: default
title: Acer Negundo Whole Beta Vulgaris Calcium Fluoride 
parent: 僅模型預測 (L5)
nav_order: 72
evidence_level: L5
indication_count: 0
---

# Acer Negundo Whole Beta Vulgaris Calcium Fluoride 
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Botanical Preparation (8 Components): No Repurposing Prediction Available

## One-Sentence Summary

This combination preparation comprises 8 botanical and mineral ingredients — Acer negundo whole, Beta vulgaris, Calcium fluoride, Horse chestnut, Krameria lappacea root, Paeonia officinalis root, Sedum acre, and Sulfur — with no registered indication in the US market.
The TxGNN model **did not generate any repurposing predictions** for this compound, and no DrugBank ID was identified, making a standard repurposing evaluation impossible at this stage.
Due to the absence of both a mapped original indication and predicted new indications, this candidate is classified as **data-insufficient** and cannot proceed further without additional prerequisite information.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (not marketed in US) |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — below L5 (no model output) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

TxGNN operates by mapping drug entities to DrugBank IDs and traversing the biomedical knowledge graph to identify candidate disease nodes. This process requires at least one resolvable DrugBank entry as an anchor point.

For this preparation, three factors blocked prediction generation:

1. **No DrugBank ID resolved.** The combination is queried as a single entity (INN string), but none of the 8 ingredients was successfully matched to a DrugBank node in this Evidence Pack (`drugbank_id: null`). Without a graph anchor, no traversal — and therefore no score — can be produced.

2. **Multi-component complexity.** This preparation contains both botanical extracts (horse chestnut, Krameria root, peony root) and homeopathic/mineral constituents (calcium fluoride, sulfur). TxGNN's training graph was built on single-molecule DrugBank entries; complex multi-ingredient preparations with heterogeneous composition fall outside the model's standard operating domain.

3. **No original indication on record.** With zero regulatory licenses and no filed indication, there is no starting node in the indication space to validate predicted connections against.

> The combination does not currently meet the minimum input requirements for TxGNN repurposing analysis.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN prediction score, no regulatory baseline, and no safety profile are available. Proceeding to clinical feasibility assessment or decision-making without these inputs would be premature and unsupported.

**To proceed, the following is needed:**

- **Identify the commercial product** associated with this ingredient combination (e.g., Weleda, Heel, or other homeopathic brand) to establish the registered original indication and jurisdiction of approval
- **Decompose into individual components** and obtain a DrugBank ID for each pharmacologically active ingredient (particularly Horse chestnut / Aesculus hippocastanum → DB01099; Krameria lappacea → search required)
- **Re-run TxGNN per component** to generate individual repurposing scores, then aggregate results at the combination level
- **Retrieve MOA for active ingredients** — Horse chestnut's aescin is a known anti-inflammatory/venotonic agent; Krameria root contains proanthocyanidins with astringent properties; these mechanistic anchors can guide hypothesis generation
- **Clarify regulatory scope** — determine whether this is a homeopathic, phytomedicinal, or conventional pharmaceutical product, as this affects which regulatory database to query and which evidence standard applies
- **Complete safety baseline** — obtain contraindications and drug interaction data for each individual active ingredient before any clinical evaluation proceeds
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

